NASDAQ:ATRA Atara Biotherapeutics Q1 2025 Earnings Report $7.61 +1.00 (+15.13%) As of 04:00 PM Eastern Earnings HistoryForecast Atara Biotherapeutics EPS ResultsActual EPS$3.50Consensus EPS -$3.07Beat/MissBeat by +$6.57One Year Ago EPSN/AAtara Biotherapeutics Revenue ResultsActual Revenue$98.10 millionExpected Revenue$4.30 millionBeat/MissBeat by +$93.80 millionYoY Revenue GrowthN/AAtara Biotherapeutics Announcement DetailsQuarterQ1 2025Date5/15/2025TimeBefore Market OpensConference Call DateThursday, May 15, 2025Conference Call Time8:30AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Atara Biotherapeutics Earnings HeadlinesAtara Biotherapeutics Announces Pricing of $16 Million OfferingMay 15 at 11:18 AM | finance.yahoo.comAtara Biotherapeutics Announces First Quarter Financial Results and Operational ProgressMay 15 at 8:35 AM | businesswire.comURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold. May 15, 2025 | Golden Portfolio (Ad)Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives $17.75 Average PT from BrokeragesMay 15 at 2:27 AM | americanbankingnews.comAtara Biotherapeutics Says FDA Lifts Clinical HoldMay 5, 2025 | marketwatch.comAtara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel)May 5, 2025 | finance.yahoo.comSee More Atara Biotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Atara Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Atara Biotherapeutics and other key companies, straight to your email. Email Address About Atara BiotherapeuticsAtara Biotherapeutics (NASDAQ:ATRA) engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.View Atara Biotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles D-Wave Pushes Back on Short Seller Case With Strong EarningsAppLovin Surges on Earnings: What's Next for This Tech Standout?Can Shopify Stock Make a Comeback After an Earnings Sell-Off?Rocket Lab: Earnings Miss But Neutron Momentum HoldsWhy Nearly 20 Analysts Raised Meta Price Targets Post-EarningsOXY Stock Rebound Begins Following Solid Earnings BeatMonolithic Power Systems: Will Strong Earnings Spark a Recovery? Upcoming Earnings Palo Alto Networks (5/20/2025)PDD (5/20/2025)Synopsys (5/20/2025)Home Depot (5/20/2025)Lowe's Companies (5/21/2025)Medtronic (5/21/2025)Mitsubishi UFJ Financial Group (5/21/2025)Sumitomo Mitsui Financial Group (5/21/2025)Snowflake (5/21/2025)TJX Companies (5/21/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
